Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses

Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses

Abstract Alongside vaccines, antiviral drugs are becoming an integral part of our response to the SARS‐CoV‐2 pandemic. Nirmatrelvir—an orally available inhibitor of the 3‐chymotrypsin‐like cysteine protease—has been shown to reduce the risk of progression to severe COVID‐19. However, the impact of n...

Full description

Bibliographic Details
Main Authors: Valeria Fumagalli, Pietro Di Lucia, Micol Ravà, Davide Marotta, Elisa Bono, Stefano Grassi, Lorena Donnici, Rolando Cannalire, Irina Stefanelli, Anastasia Ferraro, Francesca Esposito, Elena Pariani, Donato Inverso, Camilla Montesano, Serena Delbue, Stanley Perlman, Enzo Tramontano, Raffaele De Francesco, Vincenzo Summa, Luca G Guidotti, Matteo Iannacone
Format: Article
Language:English
Published: Springer Nature 2023-05-01
Series:EMBO Molecular Medicine
Subjects:
adaptive immunity
animal models
antiviral treatment
nirmatrelvir
SARS‐CoV‐2
Online Access:https://doi.org/10.15252/emmm.202317580

Internet

https://doi.org/10.15252/emmm.202317580

Similar Items